Literature DB >> 18432774

B16 as a mouse model for human melanoma.

W W Overwijk1, N P Restifo.   

Abstract

This unit details protocols for in vivo models of subcutaneous growth and pulmonary metastases of B16 melanoma. Therapeutic approaches include the use of B16.GM-CSF and rVVmTRP-1 to induce autoimmune vitiligo and tumor protection. The induction and use of gp 100-specific therapeutic cytotoxic T lymphocytes (CTL) are discussed. Methods are also included for CTL induction, isolation and testing, CTL maintenance, and adoptive transfer. Support protocols detail the testing of mouse sera for presence of MDA-specific antibodies by immunoblotting and ELISA, respectively. Additional sections, including growing B16 melanoma, enumerating pulmonary metastases, and use of recombinant viruses for vaccination, are discussed together with safety concerns.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 18432774      PMCID: PMC2763508          DOI: 10.1002/0471142735.im2001s39

Source DB:  PubMed          Journal:  Curr Protoc Immunol        ISSN: 1934-3671


  48 in total

1.  Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.

Authors:  Y Kawakami; P F Robbins; X Wang; J P Tupesis; M R Parkhurst; X Kang; K Sakaguchi; E Appella; S A Rosenberg
Journal:  J Immunol       Date:  1998-12-15       Impact factor: 5.422

2.  Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes.

Authors:  X Kang; Y Kawakami; M el-Gamil; R Wang; K Sakaguchi; J R Yannelli; E Appella; S A Rosenberg; P F Robbins
Journal:  J Immunol       Date:  1995-08-01       Impact factor: 5.422

3.  c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype.

Authors:  T Otsuka; H Takayama; R Sharp; G Celli; W J LaRochelle; D P Bottaro; N Ellmore; W Vieira; J W Owens; M Anver; G Merlino
Journal:  Cancer Res       Date:  1998-11-15       Impact factor: 12.701

4.  A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes.

Authors:  V G Brichard; J Herman; A Van Pel; C Wildmann; B Gaugler; T Wölfel; T Boon; B Lethé
Journal:  Eur J Immunol       Date:  1996-01       Impact factor: 5.532

5.  The expression of tyrosinase, tyrosinase-related proteins 1 and 2 (TRP1 and TRP2), the silver protein, and a melanogenic inhibitor in human melanoma cells of differing melanogenic activities.

Authors:  K Kameyama; C Sakai; S Kuge; S Nishiyama; Y Tomita; S Ito; K Wakamatsu; V J Hearing
Journal:  Pigment Cell Res       Date:  1995-04

6.  The tyrosinase gene family--interactions of melanogenic proteins to regulate melanogenesis.

Authors:  A Winder; T Kobayashi; K Tsukamoto; K Urabe; P Aroca; K Kameyama; V J Hearing
Journal:  Cell Mol Biol Res       Date:  1994

7.  High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy.

Authors:  H J Zeh; D Perry-Lalley; M E Dudley; S A Rosenberg; J C Yang
Journal:  J Immunol       Date:  1999-01-15       Impact factor: 5.422

8.  A reassessment of the role of B7-1 expression in tumor rejection.

Authors:  T C Wu; A Y Huang; E M Jaffee; H I Levitsky; D M Pardoll
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

9.  The central role of CD4(+) T cells in the antitumor immune response.

Authors:  K Hung; R Hayashi; A Lafond-Walker; C Lowenstein; D Pardoll; H Levitsky
Journal:  J Exp Med       Date:  1998-12-21       Impact factor: 14.307

10.  Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein.

Authors:  I Hara; Y Takechi; A N Houghton
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

View more
  150 in total

1.  Cross-presentation of cutaneous melanoma antigen by migratory XCR1+CD103- and XCR1+CD103+ dendritic cells.

Authors:  Ben Wylie; Elke Seppanen; Kun Xiao; Rachael Zemek; Damien Zanker; Sandro Prato; Bree Foley; Prue H Hart; Richard A Kroczek; Weisan Chen; Jason Waithman
Journal:  Oncoimmunology       Date:  2015-04-02       Impact factor: 8.110

2.  Behaviour of four different B16 murine melanoma cell sublines: C57BL/6J skin.

Authors:  Corina Danciu; Camelia Oprean; Dorina E Coricovac; Cioca Andreea; Anca Cimpean; Heinfried Radeke; Codruta Soica; Cristina Dehelean
Journal:  Int J Exp Pathol       Date:  2015-02-09       Impact factor: 1.925

3.  Development of tumor-infiltrating CD8+ T cell memory precursor effector cells and antimelanoma memory responses are the result of vaccination and TGF-β blockade during the perioperative period of tumor resection.

Authors:  Emily C Bellavance; Frederick J Kohlhapp; Andrew Zloza; Jeremy A O'Sullivan; James McCracken; Michael C Jagoda; Andrew T Lacek; Mitchell C Posner; Jose A Guevara-Patino
Journal:  J Immunol       Date:  2011-02-02       Impact factor: 5.422

4.  Cytomegalovirus vector expressing RAE-1γ induces enhanced anti-tumor capacity of murine CD8+ T cells.

Authors:  Tihana Tršan; Kristina Vuković; Petra Filipović; Ana Lesac Brizić; Niels A W Lemmermann; Kilian Schober; Dirk H Busch; William J Britt; Martin Messerle; Astrid Krmpotić; Stipan Jonjić
Journal:  Eur J Immunol       Date:  2017-07-04       Impact factor: 5.532

5.  Anti-cancer effects of enteric-coated polymers containing mistletoe lectin in murine melanoma cells in vitro and in vivo.

Authors:  Seung-Yeon Han; Chang-Eui Hong; Hwan-Gyu Kim; Su-Yun Lyu
Journal:  Mol Cell Biochem       Date:  2015-07-09       Impact factor: 3.396

6.  A Listeria-derived polypeptide promotes in vivo activation of NK cells for antitumor therapy.

Authors:  Amber L Ortiz; Laurel L Lenz
Journal:  Immunohorizons       Date:  2017-06-26

7.  A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment.

Authors:  Anje Cauwels; Sandra Van Lint; Geneviève Garcin; Jennyfer Bultinck; Franciane Paul; Sarah Gerlo; José Van der Heyden; Yann Bordat; Dominiek Catteeuw; Lode De Cauwer; Elke Rogge; Annick Verhee; Gilles Uzé; Jan Tavernier
Journal:  Oncoimmunology       Date:  2017-11-27       Impact factor: 8.110

8.  STING Sensing of Murine Cytomegalovirus Alters the Tumor Microenvironment to Promote Antitumor Immunity.

Authors:  Nicole A Wilski; Colby Stotesbury; Christina Del Casale; Brian Montoya; Eric Wong; Luis J Sigal; Christopher M Snyder
Journal:  J Immunol       Date:  2020-04-13       Impact factor: 5.422

9.  Murine Cytomegalovirus Infection of Melanoma Lesions Delays Tumor Growth by Recruiting and Repolarizing Monocytic Phagocytes in the Tumor.

Authors:  Nicole A Wilski; Christina Del Casale; Timothy J Purwin; Andrew E Aplin; Christopher M Snyder
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

10.  CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model.

Authors:  Marie Jordan; David J Waxman
Journal:  Cancer Lett       Date:  2015-12-03       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.